Open AccessArming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer
Author(s) -
Theresa E. Hickey,
Amy R. Dwyer,
Wayne D. Tilley
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01478-8
Subject(s) - androgen receptor , estrogen receptor , breast cancer , agonist , cancer research , estrogen , receptor , androgen , estrogen receptor beta , estrogen receptor alpha , medicine , cancer , endocrinology , hormone , prostate cancer
Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.